Related Experiment Video
Updated: Aug 7, 2025
09:58
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
13.8K
Library Screening and Preliminary Characterization of Synthetic Cannabinoids Against Prostate and Pancreatic Cancer
Deepkamal Karelia1,2, Zachary Corey1, Haifeng Wang1,3
1Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Cannabis and Cannabinoid Research
|March 7, 2023
Summary
This study identified novel cannabinoid compounds with anti-cancer activity against prostate and pancreatic cancer cells. Certain compounds induced apoptosis via CB2 receptors, while others triggered autophagy, suggesting diverse therapeutic mechanisms for solid tumors.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Previous research identified potential cannabinoid therapeutic leads for colorectal cancer.
- This study aimed to extend these findings to other solid malignancies.
Purpose of the Study:
- To identify cannabinoid compounds with cytostatic and cytocidal effects on prostate and pancreatic cancer cell lines.
- To characterize the cellular responses and molecular pathways modulated by these cannabinoid leads.
Main Methods:
- Screening of 369 synthetic cannabinoids against 4 prostate and 2 pancreatic cancer cell lines using MTT viability assay.
- Concentration-response analysis and IC50 calculation for top hits.
- Investigation of cell cycle, apoptosis, and autophagy, with receptor antagonist studies (CB1, CB2, GPR55, TRPV1).
Main Results:
- HU-331, (±)5-epi-CP55,940, and PTI-2 showed growth inhibition, consistent with prior colorectal cancer findings.
- 5-Fluoro NPB-22, FUB-NPB-22, and LY2183240 emerged as novel hits.
- (±)5-epi-CP55,940 induced CB2-mediated apoptosis; 5-fluoro NPB-22 and FUB-NPB-22 induced autophagy and cell cycle arrest, with enhanced apoptosis upon combining with hydroxychloroquine.
Conclusions:
- Novel cannabinoid leads (5-Fluoro NPB-22, FUB-NPB-22, LY2183240) were identified for prostate and pancreatic cancers.
- Mechanistic differences observed in receptor involvement and cellular responses among the identified leads.
- Further in vivo studies are warranted to evaluate safety and antitumor efficacy.
